- Clinical Trials
- April 2025
- 40 Pages
Global
From €1117EUR$1,250USD£965GBP
- Drug Pipelines
- September 2024
- 247 Pages
Global
From €7102EUR$7,950USD£6,139GBP
- Report
- June 2024
- 200 Pages
Global
From €7102EUR$7,950USD£6,139GBP
- Report
- June 2024
- 200 Pages
Global
From €7102EUR$7,950USD£6,139GBP
- Report
- June 2024
- 200 Pages
Global
From €7102EUR$7,950USD£6,139GBP
- Report
- January 2022
- 224 Pages
Global
From €6209EUR$6,950USD£5,367GBP
- Report
- January 2025
- 250 Pages
Global
From €4466EUR$4,999USD£3,860GBP
- Report
- January 2025
- 250 Pages
Global
From €4466EUR$4,999USD£3,860GBP
- Report
- May 2024
- 130 Pages
Global
From €3573EUR$3,999USD£3,088GBP
- Report
- May 2024
- 138 Pages
Global
From €3573EUR$3,999USD£3,088GBP
- Report
- October 2022
- 113 Pages
Global
From €4243EUR$4,750USD£3,668GBP
- Report
- May 2026
- 191 Pages
Australia
From €4333EUR$4,850USD£3,745GBP
- Report
- May 2026
- 196 Pages
Indonesia
From €4333EUR$4,850USD£3,745GBP
- Report
- May 2026
- 209 Pages
United Kingdom
From €4333EUR$4,850USD£3,745GBP
- Report
- March 2025
- 150 Pages
Global
From €4333EUR$4,850USD£3,745GBP
- Report
- February 2026
- 150 Pages
Canada
From €4333EUR$4,850USD£3,745GBP
- Report
- February 2026
- 150 Pages
China
From €4333EUR$4,850USD£3,745GBP
- Report
- February 2026
- 150 Pages
Germany
From €4333EUR$4,850USD£3,745GBP
- Report
- February 2026
- 150 Pages
India
From €4333EUR$4,850USD£3,745GBP
- Report
- February 2026
- 150 Pages
Japan
From €4333EUR$4,850USD£3,745GBP

Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence.
The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more